# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants

> **NCT06226064** · PHASE1 · COMPLETED · sponsor: **Vesper Biotechnologies ApS** · enrollment: 78 (actual)

## Conditions studied

- Dementia, Frontotemporal

## Interventions

- **DRUG:** VES001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06226064
- **Lead sponsor:** Vesper Biotechnologies ApS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-11
- **Primary completion:** 2024-07-26
- **Final completion:** 2024-07-26
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06226064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06226064, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06226064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*